A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse
← catalyst calendarNCT07223840 · readout ≤ 193 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
222estimated
Sites
28
Countries
China, Japan, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-03 | actual | When the study began enrolling |
| Primary completion | Feb 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Smoking
Interventions
- Drug: Brenipatide — also filed as LY3537031
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants that Achieve Carbon Monoxide (CO)-Confirmed Continuous Abstinence from Cigarette Smoking with Allowed Slips
measured Week 1 to Week 24
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed